“Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S57. https://doi.org/10.25251/skin.2.supp.57.